Schering-Plough Corporation announced that it has received antitrustclearance from the Federal Trade Commission regarding its plannedacquisition of Organon BioSciencesfrom Akzo Nobel as announced March 12. Organon BioSciences is comprised mainlyof Organon, the human pharmaceutical business, and Intervet, the animal healthbusiness. It also includes Nobilon, the human vaccine development unit, andDiosynth, the third- party manufacturing unit of Organon. Schering-Ploughreceived approval from The European Commission on Oct. 11, and continuesto expect the transaction to be completed by year-end 2007.